BCRX - BioCryst Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) 1.39B
Enterprise value 1.71B
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)5.69
Price/book (mrq)56.59
Enterprise value/revenue 5.90
Enterprise value/EBITDA -14.19

Trading information

Stock price history

Beta (5Y monthly) 2.00
52-week change 3-16.46%
S&P500 52-week change 30.07%
52-week high 315.43
52-week low 37.20
50-day moving average 38.19
200-day moving average 310.90

Share statistics

Avg vol (3-month) 32.81M
Avg vol (10-day) 32.6M
Shares outstanding 5188.94M
Implied shares outstanding 6N/A
Float 8159.94M
% held by insiders 11.07%
% held by institutions 187.07%
Shares short (14 May 2023) 432.3M
Short ratio (14 May 2023) 410.27
Short % of float (14 May 2023) 419.21%
Short % of shares outstanding (14 May 2023) 417.10%
Shares short (prior month 13 Apr 2023) 430.36M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Mar 2023


Profit margin -78.10%
Operating margin (ttm)-43.80%

Management effectiveness

Return on assets (ttm)-15.29%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)289.68M
Revenue per share (ttm)1.55
Quarterly revenue growth (yoy)37.80%
Gross profit (ttm)10.94M
EBITDA -125.37M
Net income avi to common (ttm)-226.25M
Diluted EPS (ttm)-1.20
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)398.16M
Total cash per share (mrq)2.11
Total debt (mrq)755.36M
Total debt/equity (mrq)N/A
Current ratio (mrq)5.76
Book value per share (mrq)-1.74

Cash flow statement

Operating cash flow (ttm)-131.56M
Levered free cash flow (ttm)-114.69M